You are here

Home
  • Overview
  • Agenda
  • Speakers
  • Sponsors
  • Location
  • Contact
November
01
Friday
  • 8:30 AM to 4:00 PM
  • MaRS Discovery District

The Drug Development Program – Phase 1 (DDP1) at Princess Margaret Cancer Centre is excited to announce their first symposium on Anticancer Developmental Therapeutics. It will take place on Friday, November 1, 2024 in the MaRS Discovery District Auditorium, 101 College Street, Toronto, Canada. The one-day symposium will have talks focused on immunotherapies and cancer therapeutics.      

​*****In-person registration now closed.​*****
Only VIRTUAL registration remains open.

Online registration is mandatory for all attendees. The event will also be broadcast virtually and a livestream link will be sent to remote attendees prior to the event.

Anticancer Developmental Therapeutics Symposium

Friday, November 1st, 2024 | MaRS Discovery District and Online (Hybrid Event)

8:30 AM-9:00 AM
Registration and Breakfast
9:00 AM-9:10 AM
Welcome and Opening Remarks
Keith Stewart, MD, Vice President Cancer, and Director of the Princess Margaret Cancer Centre, University Health Network
Session 1
Session Chair: Dr. Anna Spreafico, MD, PhD, Princess Margaret Cancer Centre, Toronto, ON
9:10 AM – 09:50 AM
KEYNOTE: Carrying a Cat by the Tail: What Mark Twain can teach us about the drug development of ADCs
Speaker: Anthony Tolcher, MD, NEXT Oncology, San Antonio, TX
9:50 AM – 10:20 AM
Bispecific antibodies: Precision oncology's dual strike with a single arrow
Speaker: Mercedes Herrera, MD, MSc, Princess Margaret Cancer Centre, Toronto, ON
10:20 AM – 10:50 AM
Novel IO targets
Speaker: Albiruni Razak, MBBCh, BAO, LRC SI, MRCPI, CCT, Princess Margaret Cancer Centre, Toronto, ON
10:50 AM – 11:05 AM
Panel Discussion
All morning session speakers
11:05 AM – 11:20 AM
Break
Debate Moderator: Dr. Albiruni Razak, MBBCh, BAO, LRCSI, MRCPI, CCT, Princess Margaret Cancer Centre, Toronto, ON
11:20 AM – 11:40 AM
Debate: FOR - CAR-T and other cell therapies will change treatment outcomes in solid tumours
Speaker: Mona Shafey, MD, Arthur J.E. Child Comprehensive Cancer Centre, Calgary, AB
11:40 AM – 12:00 PM
Debate: AGAINST
Speaker: Ramy Saleh, MD, MSc, McGill University Helath Centre, Montreal, QC
12:00 PM – 12:05 PM
Debate: FOR (rebuttal)
12:05 PM – 12:10 PM
Debate: AGAINST (rebuttal)
12:10 PM – 1:00 PM
Lunch
Session 2
Session Chair: Abdulazeez Salawu, MMBS, MSc, MRCP, PhD, Princess Margaret Cancer Centre, Toronto, ON
1:00 PM – 1:40 PM
Project Optimus: what have we learned so far? 
Speaker: Lillian Siu, MD, Princess Margaret Cancer Centre, Toronto, ON
1:40 PM – 2:10 PM
Increasing access and diversity in clinical trials
Speaker: Dina Lansey, MSN, Johns Hopkins Medicine, Baltimore, MD
2:10 PM – 2:25 PM
Panel Discussion
All afternoon session speakers
2:25 PM – 2:40 PM
Break
Session Chair: Dr. Erica Tsang, MD, Princess Margaret Cancer Centre, Toronto, ON
2:40 PM – 3:10 PM
A brief overview of the current landscape of cancer vaccines
Speaker: Scott Strum, MD, MSc, Princess Margaret Cancer Centre, Toronto, ON
3:10 PM – 3:40 PM
KEYNOTE: Novel Strategies in DDR Drug Development: Out with the old, in with the new?
Speaker: Timothy Yap, MD, PhD, MD Anderson Cancer Center, Houston, TX
3:40 PM – 3:55 PM
Panel Discussion
All afternoon session speakers
3:55 PM – 4:00 PM
Closing Remarks

 

*Dr. Albiruni Razak will be speaking about Novel IO Targets in place of Dr. Irene Brana.

Platinum sponsors

 
Gold sponsors

 
Pearl sponsors
Silver sponsors

 

 

In Person Location:
MaRS Discovery District Auditorium

101 College Street
Toronto, ON
M5G 1L7

DDP1 Symposium Team

Drug Development Program - Phase 1
Princess Margaret Cancer Centre
700 University Avenue, 2N-216
Toronto, ON M5G 1Z5
Email: dctsymposiums@uhn.ca

Friday, November 1, 2024 - 08:30 to 16:00